- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02548936
Efficacy and Safety of Simvastatin-ezetimibe Combination Therapy Among Patients With SLE
Efficacy and Safety of Simvastatin-ezetimibe Combination Therapy in Reduction of Progression of Atherosclerosis Among Patients With Systemic Lupus Erythematosus: A Randomized Single-Blind Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patient Registries: A convenient consecutive sampling was used to recruit participants from outpatients in department of rheumatism of PUMCH. Prior to their enrollment in the study, all patients gave written, informed consent. To minimize subject non-response or rejection, the investigators inform patients the benefits and risks, and feedback them all physical examination results for free in the recruit period.
Randomization: A randomization will be used to allocate patients into Lipid-lowering treatment group and control group.
Blind: A trained ultrasonographer who assessed carotid intima media thickness (CIMT) (at baseline and 12 months) will be blinded to all clinical and treatment information.
Statistical analysis: The characteristics of the study sample were summarized using descriptive statistics with dichotomous or ordinal data presented as percentages and continuous data as means, standard deviations, and medians, interquartile range. Differences of progression rate of atherosclerosis between intervention group and control group were assessed with either the t test or the non-parametric Wilcoxon test. A multivariable linear regression model will be used to evaluate the relationship between the progression of CIMT and intervention after controlling for confounding factors. Statistical significance was defined as a 2-tailed P value less than 0.05. All calculations were performed using SAS version 9.3.
Quality Control and Data Management: Two doctors (not the main investigator) who come from department of cardiology with the experiences of clinical trial and a data manager will be serving as Data and Safety Monitor. A monthly meeting will be set up for investigators and monitors. The monitors need to review the study protocol and set Data Safety Management plan before recruitment. Then, they need to review rates of recruitment, adherence, follow-up conditions and assess the efficacy and harm during the study. If Monitors find that the simvastatin-ezetimibe combination therapy is causing severe adverse event, then a detailed record is needed. Monitors need to inform the main investigator within 3 hours and to inform state China Food and Drug Administration within 24 hours. Interim monitoring will focus on data quality, percentage of AE or SAE, and evidence of benefit.
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Peking Union Medical College Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age ≥18 years and clinical diagnosis of SLE
- abnormal CIMT (≥0.9 mm at any site) by B-mode ultrasound
- LDL-C≥100mg/dl
- a signed written informed consent was able to be obtained.
Exclusion Criteria:
- atherosclerotic cardiovascular disease
- diabetes
- history of intolerance or allergy to the statins or ezetimibe
- had ever received statins or ezetimibe within 12 months of study entry
- LDL-C≥190mg/dl
- active infection
- ALT was higher than 2 times of the upper normal limit or CK was higher than 1.5 times of the upper normal limit.
- pregnant or lactating women
- patients with severe SLE.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lipid-lowering treatment
The Lipid-lowering treatment is Ezetimibe+Simvastatin Drug Combination by oral administration.
The patients in intervention group received simvastatin (10mg/day) + ezetimibe (20 mg/day) combined therapy for 12 month.
|
The patients in Ezetimibe+Simvastatin Drug Combination group received simvastatin (10mg/day) + ezetimibe (20 mg/day) by oral administration for 12 month.
Other Names:
|
No Intervention: No lipid-lowering treatment
Without any Lipid-lowering treatment for 12 month.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The change of carotid intima media thickness over 12 months
Time Frame: baseline, 12 months
|
CIMT(Unit: millimeter) is defined as the distance between the lumen-intima interface and the media-adventitia interface, which corresponded to the inner and outer echogenic lines seen on the B-mode ultrasound image.
|
baseline, 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The rate of abnormal elevated alanine aminotransferase (ALT)
Time Frame: 1 month
|
ALT >40U/L
|
1 month
|
The rate of abnormal elevated alanine aminotransferase
Time Frame: 3 months
|
ALT >40U/L
|
3 months
|
The rate of abnormal elevated alanine aminotransferase
Time Frame: 6 months
|
ALT >40U/L
|
6 months
|
The rate of abnormal elevated alanine aminotransferase
Time Frame: 12 months
|
ALT >40U/L
|
12 months
|
The rate of abnormal elevated creatine kinase (CK)
Time Frame: 1 month
|
CK >60U/L
|
1 month
|
The rate of abnormal elevated creatine kinase
Time Frame: 3 month
|
CK >60U/L
|
3 month
|
The rate of abnormal elevated creatine kinase
Time Frame: 6 month
|
CK >60U/L
|
6 month
|
The rate of abnormal elevated creatine kinase
Time Frame: 12 month
|
CK >60U/L
|
12 month
|
Collaborators and Investigators
Investigators
- Principal Investigator: Shuyang Zhang, MD, Peking Union Medical College Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Atherosclerosis
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Simvastatin
- Ezetimibe
- Ezetimibe, Simvastatin Drug Combination
Other Study ID Numbers
- pumch-sleas
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atherosclerosis
-
University Hospital, CaenUnknownPeripheral Arterial Disease | Atherosclerosis Obliterans | Atherosclerosis Right Leg | Atherosclerosis Left LegFrance
-
Nantes University HospitalAbbottCompletedAtherosclerosis ObliteransFrance
-
Federal University of São PauloCompletedAtherosclerosis of ArteryBrazil
-
MedtronicActive, not recruitingAtherosclerosis of Femoral Artery | Obstructive Disease | Atherosclerosis of Popliteal ArteryFrance
-
Central Hospital, Nancy, FranceSuspended
-
Cabinet de Medecine Interne Générale Demetrio PitarchCompletedAtherosclerosis of Artery
-
Emory UniversityThe Robert W. Woodruff FoundationCompleted
-
Zhejiang Zylox Medical Device Co., Ltd.RecruitingAtherosclerosis of Femoral ArteryGermany
-
VA Office of Research and DevelopmentCompletedSaphenous Vein Graft AtherosclerosisUnited States
-
Korea UniversityMinistry of Health & Welfare, KoreaCompletedAtherosclerosis | Noninvasive Imaging of AtherosclerosisKorea, Republic of
Clinical Trials on Ezetimibe+Simvastatin Drug Combination
-
Organon and CoCompletedMyocardial Infarction | Hypercholesterolemia
-
Organon and CoCompleted
-
Korea UniversityWithdrawn
-
University of Maryland, BaltimoreMerck Sharp & Dohme LLCCompletedMetabolic SyndromeUnited States
-
UMC UtrechtCompletedMetabolic SyndromeNetherlands
-
Organon and CoSchering-PloughCompletedCoronary Disease | Hypercholesterolemia
-
Fundación para el Fomento de la Investigación Sanitaria...Completed
-
Hue University of Medicine and PharmacyUniversità degli Studi di SassariUnknownChronic Kidney Diseases | HypercholesterolemiaVietnam
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Merck...CompletedDyslipidemia | Type 1 Diabetes MellitusUnited States